Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc. director Elizabeth D. Bierbower received equity-based compensation. She was granted 5,660 restricted stock units, each representing one share of common stock, and stock options covering 27,119 and 3,203 shares at an exercise price of $24.69. These awards vest on the earlier of May 21, 2027 or immediately before the company’s first annual stockholder meeting following the grant date, and the larger option grant replaces a $39,990 annual cash retainer for board and committee service.
Progyny, Inc. director Dean Lloyd H received new equity compensation consisting of common stock underlying restricted stock units and stock options. He was granted 6,792 shares of common stock underlying restricted stock units, bringing his direct common stock holdings to 26,519 shares.
He was also granted a stock option covering 28,203 shares of common stock at an exercise price of $24.69 per share, expiring on May 20, 2036. Both the restricted stock units and the option will vest on the earlier of May 21, 2027 or the calendar day immediately preceding Progyny’s first annual meeting of stockholders following the grant date, subject to his continued service.
Progyny, Inc. director Kevin K. Gordon reported equity awards and updated holdings. He received a grant of 6,792 shares of common stock in the form of restricted stock units (RSUs), each representing one share, at a stated price of $0.0000 per share. These RSUs vest on the earlier of May 21, 2027 or the calendar day immediately before Progyny’s first annual stockholders’ meeting following the grant date, subject to his continued service. Gordon also received a stock option for 30,373 shares of common stock at an exercise price of $24.6900 per share, vesting on the same schedule.
After these awards, he holds 14,818 shares of common stock directly, 12,501 shares indirectly through the Kevin Gordon Revocable Declaration of Trust where he serves as trustee, and 30,373 stock options scheduled to vest as described.
Progyny, Inc. director Roger C. Holstein reported equity compensation awards rather than market trades. He received 6,792 restricted stock units, each representing one share of common stock, and stock options covering 29,289 and 4,003 shares of common stock at an exercise price of $24.69 per share. These RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholder meeting following the grant date, provided he continues serving as a director. After the RSU grant, Holstein directly holds 28,729 shares of common stock.
Progyny, Inc. director Jeffrey G. Park reported equity compensation awards in the form of restricted stock units and stock options. He received 7,924 RSUs, each representing one share of common stock, and his common stock holdings increased to 39,981 shares following the award.
On the same date, he was granted stock options covering 31,458 shares of common stock at a conversion price of $24.69 per share, issued in lieu of a $64,985 annual cash retainer for board and committee service, and additional options covering 5,205 shares. The RSUs and options vest on the earlier of May 21, 2027 or the day immediately preceding Progyny’s first annual meeting of stockholders following the grant date, subject to his continued service.
Progyny, Inc. director Payson Norman reported new equity awards and updated his holdings. On May 21, 2026, he received 5,660 restricted stock units, each representing one share of common stock. These RSUs vest on the earlier of May 21, 2027 or the day before the first annual shareholder meeting following the grant.
Norman was also granted stock options covering 27,119 shares of common stock at an exercise price of $24.69 per share, issued in lieu of a $39,990 cash retainer for board and committee service, plus an additional option for 3,203 shares at the same exercise price. These options vest on the same schedule as the RSUs.
After these awards, Norman directly holds 12,349 shares of Progyny common stock, along with the new options. Indirectly, 122,493 shares are held by The Norman C. and Melinda B. Payson Revocable Trust and 331,363 shares are held by EVO Eagle, LLC, where he shares voting and dispositive power.
Progyny, Inc. director Cheryl Scott received new equity compensation awards. She was granted 5,660 restricted stock units, each representing one share of common stock, and 27,119 stock options with an exercise price of $24.69 per share. Both the RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholders’ meeting following the grant, subject to her continued board service. After these awards, she holds 19,772 shares of common stock directly, plus the 27,119 options.
Progyny, Inc. director Debra L. Morris reported routine equity compensation awards. She received 5,660 restricted stock units (RSUs), each representing one share of common stock, bringing her reported common stock holdings to 5,660 shares. The filing also shows two stock option grants covering 27,119 and 3,203 shares of common stock at an exercise price of $24.69 per share. According to the footnotes, these RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholders’ meeting following the grant date, contingent on her continued board service. One option grant was issued in lieu of a $39,990 annual cash retainer for board and committee service.
Progyny, Inc. announced that its board of directors has approved a share repurchase program authorizing the company to buy back up to $200 million of its common stock. The program will be funded from existing cash balances and allows repurchases in the open market, including under Rule 10b5-1 trading plans.
The timing and actual number of shares repurchased will depend on the stock price, market conditions and other factors the company considers relevant. The board may suspend or discontinue the program at any time, and there is no assurance that any specific amount of stock will be repurchased.